Clinically, single-agent oral SERD therapy tends to have a more favorable safety profile compared with an AKT or PI3K inhibitor combination, potentially sparing patients from toxicities associated with agents targeting the PI3K pathway, such as rash and hyperglycemia (29, 31). The gene discussed is PIK3CA; the disease is Hyperglycemia.